The PI3K/mTOR dual inhibitor NVP‐BEZ235 stimulates mutant p53 degradation to exert anti‐tumor effects on triple‐negative breast cancer cells

The PI3K/mTOR dual inhibitor NVP‐BEZ235 stimulates mutant p53 degradation to exert anti‐tumor effects on triple‐negative breast cancer cells

Nearly half of human cancers harbor p53 mutations, and mutant p53 (mutp53) promotes carcinogenesis, metastasis, tumor recurrence and chemoresistance. mutp53 is observed in 30% of breast carcinomas, including triple‐negative breast cancer (TNBC), and thus mutp53 is a promising target for treatment of...

Full description

Bibliographic Details
Main Authors: Jiajing Cai, Jingruo Xia, Jiang Zou, Qiang Wang, Qiang Ma, Ru Sun, Hebin Liao, Lei Xu, Dongsheng Wang, Xiaolan Guo
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:FEBS Open Bio
Subjects:
autophagy
mechanistic target of rapamycin signal transduction pathway
mutant p53
NVP‐BEZ235
protein kinase B
triple‐negative breast cancer
Online Access:https://doi.org/10.1002/2211-5463.12806

Internet

https://doi.org/10.1002/2211-5463.12806

Similar Items